1 / 6

Boceprevir in Treatment Experienced RESPOND-2

Phase 3. Treatment Experienced. Boceprevir in Treatment Experienced RESPOND-2. Bacon BR, et al. N Engl J Med. 2011;364:1207-17. Boceprevir for Retreatment of HCV Genotype 1 Infection RESPOND-2 Trial: Study Design.

hova
Download Presentation

Boceprevir in Treatment Experienced RESPOND-2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentExperienced Boceprevir in Treatment ExperiencedRESPOND-2 Bacon BR, et al. N Engl J Med. 2011;364:1207-17.

  2. Boceprevir for Retreatment of HCV Genotype 1 Infection RESPOND-2 Trial: Study Design Drug DosingBoceprevir = 800 mg three times dailyPeginterferon alfa-2b = 1.5 µg/kg once weeklyRibavirin = 600-1400 mg/day (based on weight) Source: Bacon BR, et al. N Engl J Med. 2011;364:1207-17.

  3. Boceprevir for Retreatment of HCV Genotype 1 Infection RESPOND-2 Trial: Treatment Regimens Week 0 4 8 12 24 36 48 ✔ ✔ Lead In HCV RNA PR48 Placebo Peginterferon + Ribavirin Undetectable HCV RNA at week 8&12 Stop Therapy B32 PR36-48 Boceprevir Peginterferon + Ribavirin Detectable HCV RNA at week 8, but Undetectable at week 12 Peginterferon + Ribavirin Boceprevir B44PR48 Peginterferon + Ribavirin Source: Bacon BR, et al. N Engl J Med. 2011;364:1207-17.

  4. Boceprevir for Retreatment of HCV Genotype 1 Infection RESPOND-2 Trial: Results RESPOND-2: SVR 24 by Prior Response and Regimen 17/80 95/162 107/161 15/51 72/105 77/103 23/57 30/58 2/29 *Prior Nonresponse = decrease in HCV RNA of at least 2 logs by week 12, but detectable HCV RNA level during therapy period SVR = Sustained Virologic Response; B = Boceprevir; PR = Peginterferon+ Ribavirin Source: Bacon BR, et al. N Engl J Med. 2011;364:1207-17.

  5. Boceprevir for Retreatment of HCV Genotype 1 Infection RESPOND-2 Trial: Results Based on Initial Week 4 Response RESPOND-2: SVR 24, by Initial Response and Regimen 0/12 15/46 15/44 17/67 80/110 90/114 *Poor Initial Response to PR = decrease in HCV RNA level < 1 log10 IU/ml after 4 week lead in ^Good Initial Response to PR = decrease in HCV RNA level >1 log10 IU/ml after 4 week lead in SVR = Sustained Virologic Response; B = Boceprevir; PR = Peginterferon + Ribavirin Source: Bacon BR, et al. N Engl J Med. 2011;364:1207-17.

  6. Boceprevir for Retreatment of HCV Genotype 1 Infection RESPOND-2 Trial: Conclusions Source: Bacon BR, et al. N Engl J Med. 2011;364:1207-17.

More Related